OHSU researcher Paul Spellman, Ph.D. is among the contributors to a breakthrough discovery that reveals genomic drivers of a poorly understood form of kidney cancer, primary papillary renal cell carcinoma. The findings, published yesterday in the New England Journal of Medicine, identify many of the altered genes and cell signaling pathways that drive this disease. Spellman, a professor of molecular and medical genetics in the School of Medicine and a member of the OHSU Knight Cancer Institute, along with co-author W. Marston Linehan, M.D. at the National Cancer Institute, worked with physicians and investigators from 39 institutions participating in the Cancer Genome Atlas Research Network to release these findings. Results of this comprehensive study should help physicians better understand how to diagnose and treat patients with papillary kidney tumors, which account for 15 percent of kidney cancer cases. Read more about the discovery here.
About the author
Julie Rogers is Research Development Associate in the Office of Research Funding & Development Services.
Other posts by this author:
- Reminder: RCR and human subjects training deadline, May 31
- OHSU Center for Women’s Health Circle of Giving awards two research grants
- Gerlinger Research Award applications due June 4, 2017
- Presidential bridge funding applications due June 15
- Pew Scholars Program for junior faculty; internal applications due June 5